|
|
|
| Research on concerted application rule of Chinese patent drug containing Astragali Radix based on data mining |
| LI Yang MA Wei |
Heilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin 150040, China
|
|
|
|
Abstract Objective To explore the concerted application characteristics and formulation rules of Astragali Radix in Chinese patent drugs in China at present. Methods Chinese Pharmacopoeia and Traditional Chinese Medicine Prescriptions were used as data sources. Indicative diseases, applicable syndromes, commonly used drug pairs, and concerted application rules of Chinese patent drug containing Astragali Radix were explored by using frequency analysis, association rule analysis, and network atlas analysis. Results Five hundred and seventy kinds of Astragali Radix in Chinese patent drugs were collected and sorted out, involving 624 kinds of traditional Chinese medicines. The drug nature and flavour were mainly warm and sweet, and the channel tropisms were mainly liver, kidney and lung. There were 155 main diseases, mainly including fatigue, dizziness, etc. There were 149 corresponding syndromes, with the highest frequency of syndrome of deficiency of both qi and blood occurring. It was found that common concerted application drugs include Astragali Radix and Angelicae Sinensis Radix through correlation analysis. Sixteen core drug combinations and 15 association rules were obtained. The compatibility network analysis of Chinese patent medicine containing Astragali Radix showed that the core compatibility of Chinese patent medicine containing Astragali Radix showed when the support degree was ≥35%. Analysis on the compatibility of Chinese prescription drugs containing Astragali Radix showed that the core drugs for treating consumptive disease, vertigo, syndrome of deficiency of both qi and blood, and syndrome of deficiency of kidney yang all contained Angelicae Sinensis Radix, Astragali Radix and Rehmanniae Radix Praeparata. Conclusion Astragali Radix in Chinese patent drugs is mainly composed of Astragali Radix with drugs of supplementing qi and blood, tonifying deficiency and nourishing yin, which has prominent therapeutic effect on diseases of syndrome of deficiency of both qi and blood, syndrome of deficiency of kidney yang and syndrome of deficiency of both qi and yin.
|
|
|
|
|
|
[1] 国家药典委员会.中华人民共和国药典[S].一部.北京：中国医药科技出版社，2020：159，315.
[2] 严健民.五十二病方注补译[M].北京：中医古籍出版社，2005：139.
[3] 神农本草经[M].北京：中国中医药出版社，2019.
[4] 李时珍.本草纲目[M].北京：中国中医药出版社，1998.
[5] 南京中医药大学.中药大辞典[M].上海：上海科学技术出版社，2006：2813.
[6] 国家中医药管理局《中华本草》编委会.中华本草[M].上海：上海科学技术出版社，1999：2974.
[7] 戴泽琦，徐思敏，吴雪，等.多准则决策分析用于中成药临床综合评价的建议[J].中国中药杂志，2022，47（12）：3155-3160.
[8] 国家药典委员会.药品标准·中药成方制剂[S].1989.
[9] 国家卫生健康委员会，国家中医药管理局.中医临床诊疗术语·第2部分：证候[S].2020.
[10] 国家卫生健康委员会，国家中医药管理局.中医临床诊疗术语·第1部分：疾病[S].2020.
[11] 黄正慧.PBC和AIH中医证型分布规律及基于数据挖掘的用药规律研究[D].北京：北京中医药大学，2021.
[12] 刘子馨，胥淑娟，李磊，等.2020年版《中国药典》（一部）中儿童咳嗽中成药的情况分析[J].中国实验方剂学杂志，2021，27（17）：160-167.
[13] 王永康，李莉，王艳国.基于《中华医典》文献挖掘的膝痹用药规律研究[J].天津中医药，2022，39（6）：724-728.
[14] 王敏，刘欢欢，张婷，等.基于化学特征和核心功效的经典名方清胃散中地黄炮制品研究[J].中草药，2022，53（13）：3940-3952.
[15] 徐婕，沈雁.从脾胃论治心悸[J].医学综述，2022，28（4）：761-765.
[16] 白璐铭，尚德阳.肾阳虚证的病位证候要素探析[J/OL].辽宁中医药大学学报：1-8[2022-07-27]. http：//kns.cnki.net/kcms/detail/21.1543.R.20220613.1626.020.html.
[17] 刘怀智，周海娟，陈刚，等.参麦地黄汤联合常规治疗对气阴两虚证早期糖尿病肾病患者的临床疗效[J].中成药，2021，43（7）：1759-1763.
[18] 王丽红，刘超，王兴臣，等.《伤寒杂病论》应用当归考辨[J].河南中医，2022，42（8）：1135-1138.
[19] 李霞，曹旺，唐标，等.基于网络药理学探讨黄芪-当归配伍活性成分改善血管内膜增生的作用机制[J].中草药，2020，51（15）：3987-3995.
[20] 向璐，张巧艳，赵琦明，等.黄芪-当归化学成分、药理作用及临床应用的研究进展[J].中草药，2022，53（7）：2196-2213.
[21] 唐迪文，陈碧华，钱郑凤.补中益气汤治疗气血亏虚型眩晕临床研究[J].河南中医，2015，35（1）：65-67.
[22] 孙启明.内补黄耆汤源流试考[J].中成药研究，1984（11）：32-33.
[23] 梅莎莎，宋恩峰.健脾生血颗粒治疗气血两虚型癌因性疲乏的临床疗效研究[J].世界中医药，2022，17（18）：2623-2627.
[24] 胡嘉元，雷飞，底君，等.生发乌发经典中医方剂的现代临床应用[J].中医药导报，2016，22（6）：110-112，117.
[25] 张英杰，张宗礼.黄芪建中汤加减联合西医常规治疗脾肾阳虚型肾病综合征的经验总结[J].内蒙古中医药，2019， 38（12）：91-92.
[26] 郭小磊，郭文娟.基于VOSviewer的黄芪治疗肾病研究现状可视化分析[J].中国医药科学，2021，11（22）：205- 208，222. |
|
|
|
